Inventiva announces the issuance of royalty certificates for an amount of 20.1 million euros

Biopharmaceutical company Inventiva announced the issuance of royalty certificates worth €20.1 million. These certificates were subscribed by Samsara BioCapital and existing shareholders such as BVF Partners, NEA, Sofinnova and Yiheng.

These royalty certificates will entitle their holders to 3% of future net sales of lanifibranor in the United States, European Union and United Kingdom over a period of 14 years. Lanifibranor is currently undergoing a Phase III trial for the treatment of non-alcoholic steatohepatitis.

Frédéric Cren, CEO of Inventiva, said this agreement extends Inventiva's cash position until September 2024. The company is also considering other strategic and financial options to continue the development of lanifibranor.